Objective To retrospectively analyze clinical data of 207 patients with gynecologic malignancy.Methods All cases were diagnosed from 2010 to 2012,and were divided into four groups by ages (≤20-year-old age,20-40-year-old age,40-60-year-old age and ≥60-year-old age).Their clinical characters were reviewed and compared.Results The 40-60-year-old age group had the greatest number of cases for the entire cohort 49.8％ (103/207).The most common primary site of the ≤20-year-old age group was ovary (75.0％).Cervix 36.4％(24/66) and ovary 30.3％(20/66) were the common primary site of the 20-40-year-old age group.Endometrium,cervix and ovary were common in the 40-60-year-old age group with 27.2％,26.2％,23.3％,respectively.Ovary,endometrium and cervix were common in the last group with 29.4％,26.5％ and 20.6％,respectively.In the ≤20-year-old age group,the germ cell was the most common histology among ovarian malignancies (66.7％),and the epithelial tumor was the most common tumor in the other groups.Conclusions Carcinoma of cervix,ovary and endometrium are the most common gynecologic malignancies and 40-60-year-old age is the high-risk age.We should strengthen the health education and physical examination for young women.

Objective To explore the clinical effect and adverse reaction on hysteromyoma patients treated with mifepristone of different periods.Methods Forty-seven patients with conservative treatment were treated with mifepristone of 10 mg/d for 9 months,and 1 period was 3 months.Uterine volume,fibroid volume and hemoglobin (Hb) were detected after each period,and clinical effect and adverse reaction were also observed.Results All patients were completed 3 periods,and clinical symptoms improved.Uterine volume and fibroid volume reduced gradually,and Hb increased gradually during treatment.Uterine volume and fibroid volume reduced by 41.54％ and 46.53％ respectively.All indicators had significant changes at first period and second period,compared with without treatment and first period gradually (P ＜ 0.05).There was no significant difference in adverse reaction among different periods (P ＞ 0.05).Conclusions The clinical effect on hysteromyoma treated with mifepristone of long-period was effective,and adverse reaction did not significantly increase.Long-period treatment with mifepristone provide a conservative treatment for near menopausal hysteromyoma patients.

Objective:To compare the pathological results and complications of limited and extended pelvic lymph node dissection among high-risk prostate cancer patients, and to explore the risk factors that affect the rate of lymph node metastasis in high-risk prostate cancer patients.Methods:The data of 800 high-risk prostate cancer patients who underwent radical prostatectomy and pelvic lymph node dissection from January 2016 to December 2020 in three affiliated hospital of Sun Yat-sen University were analyzed retrospectively. According to the scope of pelvic lymph node dissection, they were divided into limited pelvic lymph node dissection (LPLND) group and extended pelvic lymph node dissection (EPLND) group. There were 172 patients underwent LPLND, and 628 patients underwent EPLND.The age of the patients in the LPLND group was 67 (62, 72) years old, diagnosed PSA 20.7 (10.9, 54.8) ng/ml. The biopsy Gleason score 6 in 22 cases, 7 in 59 cases, 8 in 56 cases and 9-10 in 35 cases.The clinical T stage: T 1 in 29 cases, T 2 in 102 cases, T 3 in 37 cases, T 4 in 4 cases; N 0 in 160 cases and N 1 in 12 cases. 50 patients received neoadjuvant hormonal therapy. The age of patients in the EPLND group was 67 (63, 72) years old, diagnosed PSA was 23.9 (14.0, 46.8) ng/ml. Biopsy Gleason Score 6 in 51 cases, 7 in 194 cases, 8 in 218 cases and 9-10 in 165 cases. Clinical T stage: T 1 in 114 cases, T 2 in 341 cases, T 3 in 144 cases, T 4 in 29 cases; N 0 in 526 cases and N 1 in 102 cases.158 patients received neoadjuvant hormonal therapy. There were no significant differences in the age, PSA, puncture Gleason score, clinical T stage, and whether or not to receive neoadjuvant hormonal therapy between the two groups of patients ( P>0.05). The difference in clinical N staging was statistically significant ( P=0.002). The number of postoperative lymph nodes, positive pelvic lymph nodes and postoperative complications and other related clinical and pathological data of the two groups were analyzed. Multivariate logistic regression was used to analyze the risk factors of patients with positive lymph nodes. Results:The median number of lymph nodes harvested [13(8, 19)vs. 6(4, 13), P<0.001] and the rate of positive lymph node cases[31.2%(196/628) vs. 10.5%(18/172), P<0.001] in the EPLND group was significantly higher than those in the LPLND group. Preoperative PSA, clinical N staging, Gleason score, and way of lymph node dissection were independent risk factors for postoperative positive pelvic lymph node in high-risk prostate cancer patients. Compared with the LPLND group, the ELPND group had a higher postoperative complication rate [19.9%(125/628) vs. 11.0%(11/172), P=0.007]. Conclusions:Compared with the LPLND, EPLND in high-risk prostate cancer patients can harvest more lymph nodes and increase the detection rate of positive lymph nodes. The complications of EPLND were higher than those of LPLND. Preoperative PSA, clinical N stage, Gleason score, and the way of lymph node dissection are independent risk factors for positive pelvic lymph node dissection.